Pediatric RSV Postpandemic Findings from Pulmonology Advisor

Pulmonology Advisor recently published an article titled “Pediatric RSV Postpandemic: Many More Hospital, ICU Admissions and ED Visits.” This report highlights a concerning trend: a significant rise in RSV (respiratory syncytial virus) infections among children following the COVID-19 pandemic.

The study, as reported by Pulmonology Advisor, reveals a substantial increase in hospitalizations and ICU admissions for RSV compared to pre-pandemic levels. Emergency department visits for RSV have also skyrocketed.

The postpandemic pediatric RSV season saw a 3.5-fold increase in ED visits for RSV, an 86.7% increase in hospital admissions, and a 43.5% increase in ICU admissions.

Children with RSV were significantly older during the 2022 to 2023 postpandemic season vs the prepandemic seasons (median [IQR], 11.3 [4.1-26.6] vs 6.8 [2.6-16.8] months; P <.001). In addition, more previously healthy children were hospitalized in the 2022 to 2023 season compared with prepandemic, and a lower proportion had a preexisting comorbid condition (17.6% vs 21.8%; P <.001).

We encourage all APAPP members to review this important news. Understanding the current landscape of pediatric RSV cases will be crucial for effective patient care during this upcoming season.

Access the full article here: https://www.pulmonologyadvisor.com/news/pediatric-rsv-postpandemic-many-more-hospital-and-ed-visits/

P.S. Do you have any insights or experiences related to the recent rise in pediatric RSV cases? We want to hear from you. Consider joining APAPP’s Pediatric Subspecialty Committee. Send us an email at